A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy
暂无分享,去创建一个
J. Carpten | D. Craig | S. Byron | G. Weiss | T. Whitsett | J. Kiefer | J. Aldrich | A. Sangal | Heather Barilla
[1] Rebecca F. Halperin,et al. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. , 2017, Genome research.
[2] G. Fontanini,et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D , 2016, The Journal of pathology.
[3] C. Rudin,et al. Small Cell Lung Cancer , 2016, Seminars in Respiratory and Critical Care Medicine.
[4] R. Califano,et al. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? , 2016, ESMO Open.
[5] D. Jäger,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[6] F. de Marinis,et al. Cellular and molecular biology of small cell lung cancer: an overview. , 2016, Translational lung cancer research.
[7] Z. Lohinai,et al. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC) , 2016, PloS one.
[8] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[9] Martin Vingron,et al. Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.
[10] V. Shukla,et al. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. , 2015, Current cancer drug targets.
[11] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[12] Aleksandar Sekulic,et al. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team , 2015, Molecular Cancer Therapeutics.
[13] S. Jalal,et al. Novel therapies in small cell lung cancer. , 2015, Translational lung cancer research.
[14] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[15] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Nackaerts,et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[18] Winnie S. Liang,et al. A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and Challenges , 2013, PloS one.
[19] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Ardizzoni,et al. Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.